Current guidelines and prospects for using novel oral anticoagulants for nonvalvular atrial fibrillation
The capabilities of antithrombotic therapy to prevent systemic thromboembolic events in nonvalvular atrial fibrillation (AF) are substantially extended after clinically introducing novel oral anticoagulants (NOACs), such as dabigatran, rivaroxaban, and apixaban. World clinical experience with NOACs...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2014-12-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/448 |